Covington, La. based marine engineering and services firm Baker Marine Solutions (BMS) has unveiled a new pipe mill barge concept design targeting uptake in the U.S. offshore wind industry. BMS ...
Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for $14 billion, the companies said today, in a deal intended to bolster the buyer’s neurological drug portfolio with Karuna’s ...
Bristol Myers Squibb Co. (BMS) has terminated its $1.3 billion-plus deal for Agenus Inc.’s anti-TIGIT bispecific antibody AGEN-1777 as part of a promised belt-tightening. In May 2021, BMS paid Agenus ...
As he talks about the future of cell therapy, the enthusiasm of Cellares CEO Fabian Gerlinghaus is unmistakable. “There’s about 2,800 cell therapies in development worldwide,” Gerlinghaus said in an ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) is today holding a Research and Development (R&D) Day in New York to discuss the company’s R&D strategy and capabilities and to ...
With its $76 billion purchase of Celgene in 2019, BMS shored up its late-stage pipeline with a drug program that promised reliable long-term revenues. While the acquisition of Celgene ran into ...
Bristol-Myers Squibb CEO Giovanni Caforio was less than 10 minutes into a special shareholders meeting on the company's proposed $74 billion acquisition of Celgene when a broker interrupted his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results